Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking

Antibody agonists targeting tumor necrosis factor (TNF) superfamily receptors, including CD40, are being tested therapeutically as anticancer agents. Studies in mice have shown that anti-CD40 monoclonal antibody (mAb) requires Fc-receptor (FcR) engagement to activate antitumor immunity. In contrast,...

Descripción completa

Detalles Bibliográficos
Autores principales: Richman, Lee P, Vonderheide, Robert H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091558/
https://www.ncbi.nlm.nih.gov/pubmed/25097801
http://dx.doi.org/10.4161/onci.28610
_version_ 1782480781816365056
author Richman, Lee P
Vonderheide, Robert H
author_facet Richman, Lee P
Vonderheide, Robert H
author_sort Richman, Lee P
collection PubMed
description Antibody agonists targeting tumor necrosis factor (TNF) superfamily receptors, including CD40, are being tested therapeutically as anticancer agents. Studies in mice have shown that anti-CD40 monoclonal antibody (mAb) requires Fc-receptor (FcR) engagement to activate antitumor immunity. In contrast, we have reported that clinically active anti-human CD40 mAb CP-870,893 does not require FcR crosslinking, a finding with translational implications.
format Online
Article
Text
id pubmed-4091558
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-40915582014-08-05 Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking Richman, Lee P Vonderheide, Robert H Oncoimmunology Author's View Antibody agonists targeting tumor necrosis factor (TNF) superfamily receptors, including CD40, are being tested therapeutically as anticancer agents. Studies in mice have shown that anti-CD40 monoclonal antibody (mAb) requires Fc-receptor (FcR) engagement to activate antitumor immunity. In contrast, we have reported that clinically active anti-human CD40 mAb CP-870,893 does not require FcR crosslinking, a finding with translational implications. Landes Bioscience 2014-04-29 /pmc/articles/PMC4091558/ /pubmed/25097801 http://dx.doi.org/10.4161/onci.28610 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Richman, Lee P
Vonderheide, Robert H
Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking
title Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking
title_full Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking
title_fullStr Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking
title_full_unstemmed Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking
title_short Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking
title_sort anti-human cd40 monoclonal antibody therapy is potent without fcr crosslinking
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091558/
https://www.ncbi.nlm.nih.gov/pubmed/25097801
http://dx.doi.org/10.4161/onci.28610
work_keys_str_mv AT richmanleep antihumancd40monoclonalantibodytherapyispotentwithoutfcrcrosslinking
AT vonderheideroberth antihumancd40monoclonalantibodytherapyispotentwithoutfcrcrosslinking

Ejemplares similares